The global veterinary oncology market was valued at $297.30 million in 2020, and is estimated to reach $819.84 million by 2030, growing at a CAGR of 10.8% from 2021 to 2030.
Veterinary is defined as the injury, disease, and treatment of domestic and farm animals. Veterinary oncology deals with the treatment and diagnosis of cancer in animals. Skin tumors, mammary tumors, endocrine tumors, osteosarcoma, hemangiosarcoma, and lymphosarcoma are some of the cancers prevalent among animals. Dogs and cats are more vulnerable to cancers. Dogs are 35 times more vulnerable to develop skin cancer, as compared to humans, due to regular and longtime exposure to sun rays.
The growth of the global veterinary oncology market is majorly driven by alarming increase in the prevalence of cancer in animal, such as lymphoma, skin tumor, mammary tumors, & osteosarcoma; rise in government initiative for development of veterinary cancer treatment; surge in number of pet clinic for treatment; rise in expenditure on animal healthcare; and rise in adoption of animals. For instance, according to the American Veterinary Medical Association (AVMA), approximately half of the dogs above the age of 10 are diagnosed with cancer. Moreover, in July 2019, the National Cancer Institute announced an initiative for helping dogs that are diagnosed with cancer, by providing appropriate treatment. Rise in number of pet clinics and surge in demand for veterinary oncology, diagnostic, and treatment procedure drive the growth of the market. For instance, in February 2021, Dogs Cats and Animal (DCC) Hospital, is expected to launch a chain of multi-specialist hospital in India. Hospital will include advanced infrastructure and devices for the treatment of animals. Thus, increase in the number of veterinary hospitals and rise in number of animals such as dogs and cats are expected to propel the growth of the market.
Increase in the focus on animal safety and surge in demand for innovative pet care & medication are the major factors that drive the global veterinary oncology market. Moreover, increase in the number of veterinary clinical studies significantly contributes toward the market growth. Veterinary clinical studies aim to evaluate the safety and efficacy of different treatment of oncology in animals. Rise in demand for veterinary care therapy for effective treatment acts a key driving force for the expansion of the global market. Furthermore, the rise in funds by government and private organizations to develop veterinary care centers are expected to boost the market growth. According to the National Canine Cancer Foundation, the development of an autologous tumor lysate vaccine for immunotherapy of hemangiosarcoma was funded $32,453 by PET cancer awareness grant courtesy of Petco Foundation and Blue Buffalo and the chase away K9 cancer fund.
In addition, advancements in R&D activities and rise in number of clinical studies by researcher focused on veterinary oncology treatment in emerging nations are anticipated to provide lucrative opportunities for the market expansion. For instance, in September 2020, Animal Life Science, a pharmaceutical and nutritional development company, announced the comparative oncology trial of ALS101, which is conducted by researchers at Virginia-Maryland college of Veterinary Medicine and Wake Forest Baptist Comprehensive cancer centers. The drug candidate is a combination of two brain cancer drugs, which show promising results in dogs suffering from malignant gliomas.
However, high cost associated with chemotherapies, targeted therapies for treatment of cancer in animal, and side effects of drugs used for veterinary oncology treatment are anticipated to hinder the market growth. On the contrary, the rise in number of veterinary cancer centers, advancements of technology for development of cancer therapy, and increase in awareness among the population for management of pet illness augment the growth of the veterinary oncology sector. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities in the veterinary oncology market.
The global veterinary oncology market is segmented into therapy, animal type, cancer, and region. By therapy, the market is categorized into surgery, radiology, chemotherapy, and others. On the basis of animal type, it is categorized into canine and feline.
Depending on cancer, it is fragmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global veterinary oncology market are Accuray Incorporated, Boehringer Ingelheim International GmbH, Elanco, Karyopharm Therapeutics, Inc., Morphogenesis, Inc., Nippon Zenyaku Kogyo Co., PetCure Oncology, Regeneus Ltd., Varian Medical System, Inc., and Zoetis.
Veterinary is defined as the injury, disease, and treatment of domestic and farm animals. Veterinary oncology deals with the treatment and diagnosis of cancer in animals. Skin tumors, mammary tumors, endocrine tumors, osteosarcoma, hemangiosarcoma, and lymphosarcoma are some of the cancers prevalent among animals. Dogs and cats are more vulnerable to cancers. Dogs are 35 times more vulnerable to develop skin cancer, as compared to humans, due to regular and longtime exposure to sun rays.
The growth of the global veterinary oncology market is majorly driven by alarming increase in the prevalence of cancer in animal, such as lymphoma, skin tumor, mammary tumors, & osteosarcoma; rise in government initiative for development of veterinary cancer treatment; surge in number of pet clinic for treatment; rise in expenditure on animal healthcare; and rise in adoption of animals. For instance, according to the American Veterinary Medical Association (AVMA), approximately half of the dogs above the age of 10 are diagnosed with cancer. Moreover, in July 2019, the National Cancer Institute announced an initiative for helping dogs that are diagnosed with cancer, by providing appropriate treatment. Rise in number of pet clinics and surge in demand for veterinary oncology, diagnostic, and treatment procedure drive the growth of the market. For instance, in February 2021, Dogs Cats and Animal (DCC) Hospital, is expected to launch a chain of multi-specialist hospital in India. Hospital will include advanced infrastructure and devices for the treatment of animals. Thus, increase in the number of veterinary hospitals and rise in number of animals such as dogs and cats are expected to propel the growth of the market.
Increase in the focus on animal safety and surge in demand for innovative pet care & medication are the major factors that drive the global veterinary oncology market. Moreover, increase in the number of veterinary clinical studies significantly contributes toward the market growth. Veterinary clinical studies aim to evaluate the safety and efficacy of different treatment of oncology in animals. Rise in demand for veterinary care therapy for effective treatment acts a key driving force for the expansion of the global market. Furthermore, the rise in funds by government and private organizations to develop veterinary care centers are expected to boost the market growth. According to the National Canine Cancer Foundation, the development of an autologous tumor lysate vaccine for immunotherapy of hemangiosarcoma was funded $32,453 by PET cancer awareness grant courtesy of Petco Foundation and Blue Buffalo and the chase away K9 cancer fund.
In addition, advancements in R&D activities and rise in number of clinical studies by researcher focused on veterinary oncology treatment in emerging nations are anticipated to provide lucrative opportunities for the market expansion. For instance, in September 2020, Animal Life Science, a pharmaceutical and nutritional development company, announced the comparative oncology trial of ALS101, which is conducted by researchers at Virginia-Maryland college of Veterinary Medicine and Wake Forest Baptist Comprehensive cancer centers. The drug candidate is a combination of two brain cancer drugs, which show promising results in dogs suffering from malignant gliomas.
However, high cost associated with chemotherapies, targeted therapies for treatment of cancer in animal, and side effects of drugs used for veterinary oncology treatment are anticipated to hinder the market growth. On the contrary, the rise in number of veterinary cancer centers, advancements of technology for development of cancer therapy, and increase in awareness among the population for management of pet illness augment the growth of the veterinary oncology sector. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities in the veterinary oncology market.
The global veterinary oncology market is segmented into therapy, animal type, cancer, and region. By therapy, the market is categorized into surgery, radiology, chemotherapy, and others. On the basis of animal type, it is categorized into canine and feline.
Depending on cancer, it is fragmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global veterinary oncology market are Accuray Incorporated, Boehringer Ingelheim International GmbH, Elanco, Karyopharm Therapeutics, Inc., Morphogenesis, Inc., Nippon Zenyaku Kogyo Co., PetCure Oncology, Regeneus Ltd., Varian Medical System, Inc., and Zoetis.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global veterinary oncology market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global veterinary oncology market.
KEY MARKET SEGMENTS
By Therapy
- Surgery
- Radiology
- Chemotherapy
- Others
By Animal Type
- Canine
- Surgery
- Radiology
- Chemotherapy
- Others
- Feline
- Surgery
- Radiology
- Chemotherapy
- Others
By Cancer
- Lymphoma
- Mast Cell Cancer
- Mammary & Squamous Cell Cancer
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Accuray Incorporated
- Boehringer Ingelheim International GmbH
- Elanco
- Karyopharm Therapeutics, Inc.
- Morphogenesis, Inc.
- Nippon Zenyaku Kogyo Co.
- PetCure Oncology
- Regeneus Ltd.
- Varian Medical System, Inc.
- Zoetis
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of cancer in animal
3.5.1.2. Growth in veterinary healthcare expenditure and development in pet insurance policy
3.5.1.3. Increase in R&D activities for veterinary cancer therapy
3.5.2. Restraint
3.5.2.1. High cost of therapies for the treatment of veterinary oncology
3.5.3. Opportunity
3.5.3.1. Increase in number of veterinary clinical trial studies
3.5.4. Impact analysis
3.6. Impact analysis of COVID-19 on the veterinary oncology market
CHAPTER 4: VETERINARY ONCOLOGY MARKET, BY THERAPY
4.1. Overview
4.1.1. Market size and forecast
4.2. Surgery
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Radiology
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.5. Chemotherapy
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
CHAPTER 5: VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Canine
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by region
5.2.2.1. Canine by therapy
5.2.3. Market analysis, by country
5.3. Feline
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by region
5.3.2.1. Feline by therapy
5.3.3. Market analysis, by country
CHAPTER 6: VETERINARY ONCOLOGY MARKET, BY CANCER
6.1. Overview
6.1.1. Market size and forecast
6.2. Lymphoma
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. Mast Cell Cancer
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country
6.4. Mammary and Squamous Cell Cancer
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market analysis, by country
6.5. Others
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market analysis, by country
CHAPTER 7: VETERINARY ONCOLOGY MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America veterinary oncology market, by therapy
7.2.3. North America veterinary oncology market, by animal type
7.2.4. North America veterinary oncology market, by cancer
7.2.5. Market size and forecast, by country
7.2.5.1. U. S.
7.2.5.1.1. U. S. veterinary oncology market, by therapy
7.2.5.1.2. U. S. veterinary oncology market, by animal type
7.2.5.1.3. U. S. veterinary oncology market, by cancer
7.2.5.2. Canada
7.2.5.2.1. Canada veterinary oncology market, by therapy
7.2.5.2.2. Canada veterinary oncology market, by animal type
7.2.5.2.3. Canada veterinary oncology market, by cancer
7.2.5.3. Mexico
7.2.5.3.1. Mexico veterinary oncology market, by therapy
7.2.5.3.2. Mexico veterinary oncology market, by animal type
7.2.5.3.3. Mexico veterinary oncology market, by cancer
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe veterinary oncology market, by therapy
7.3.3. Europe veterinary oncology market, by animal type
7.3.4. Europe veterinary oncology market, by cancer
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Germany veterinary oncology market, by therapy
7.3.5.1.2. Germany veterinary oncology market, by animal type
7.3.5.1.3. Germany veterinary oncology market, by cancer
7.3.5.2. France
7.3.5.2.1. France veterinary oncology market, by therapy
7.3.5.2.2. France veterinary oncology market, by animal type
7.3.5.2.3. France veterinary oncology market, by cancer
7.3.5.3. UK
7.3.5.3.1. UK veterinary oncology market, by therapy
7.3.5.3.2. UK veterinary oncology market, by animal type
7.3.5.3.3. UK veterinary oncology market, by cancer
7.3.5.4. Italy
7.3.5.4.1. Italy veterinary oncology market, by therapy
7.3.5.4.2. Italy veterinary oncology market, by animal type
7.3.5.4.3. Italy veterinary oncology market, by cancer
7.3.5.5. Spain
7.3.5.5.1. Spain veterinary oncology market, by therapy
7.3.5.5.2. Spain veterinary oncology market, by animal type
7.3.5.5.3. Spain veterinary oncology market, by cancer
7.3.5.6. Rest of Europe
7.3.5.6.1. Rest of Europe veterinary oncology market, by therapy
7.3.5.6.2. Rest of Europe veterinary oncology market, by animal type
7.3.5.6.3. Rest of Europe veterinary oncology market, by cancer
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific veterinary oncology market, by therapy
7.4.3. Asia-Pacific veterinary oncology market, by animal type
7.4.4. Asia-Pacific veterinary oncology market, by cancer
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Japan veterinary oncology market, by therapy
7.4.5.1.2. Japan veterinary oncology market, by animal type
7.4.5.1.3. Japan veterinary oncology market, by cancer
7.4.5.2. China
7.4.5.2.1. China veterinary oncology market, by therapy
7.4.5.2.2. China veterinary oncology market, by animal type
7.4.5.2.3. China veterinary oncology market, by cancer
7.4.5.3. Australia
7.4.5.3.1. Australia veterinary oncology market, by therapy
7.4.5.3.2. Australia veterinary oncology market, by animal type
7.4.5.3.3. Australia veterinary oncology market, by cancer
7.4.5.4. India
7.4.5.4.1. India veterinary oncology market, by therapy
7.4.5.4.2. India veterinary oncology market, by animal type
7.4.5.4.3. India veterinary oncology market, by cancer
7.4.5.5. South Korea
7.4.5.5.1. South Korea veterinary oncology market, by therapy
7.4.5.5.2. South Korea veterinary oncology market, by animal type
7.4.5.5.3. South Korea veterinary oncology market, by cancer
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Rest of Asia-Pacific veterinary oncology market, by therapy
7.4.5.6.2. Rest of Asia-Pacific veterinary oncology market, by animal type
7.4.5.6.3. Rest of Asia-Pacific veterinary oncology market, by cancer
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA veterinary oncology market, by therapy
7.5.3. LAMEA veterinary oncology market, by animal type
7.5.4. LAMEA veterinary oncology market, by cancer
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Brazil veterinary oncology market, by therapy
7.5.5.1.2. Brazil veterinary oncology market, by animal type
7.5.5.1.3. Brazil veterinary oncology market, by cancer
7.5.5.2. Saudi Arabia
7.5.5.2.1. Saudi Arabia veterinary oncology market, by therapy
7.5.5.2.2. Saudi Arabia veterinary oncology market, by animal type
7.5.5.2.3. Saudi Arabia veterinary oncology market, by cancer
7.5.5.3. South Africa
7.5.5.3.1. South Africa veterinary oncology market, by therapy
7.5.5.3.2. South Africa veterinary oncology market, by animal type
7.5.5.3.3. South Africa veterinary oncology market, by cancer
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Rest of LAMEA veterinary oncology market, by therapy
7.5.5.4.2. Rest of LAMEA veterinary oncology market, by animal type
7.5.5.4.3. Rest of LAMEA veterinary oncology market, by cancer
CHAPTER 8: COMPANY PROFILES
8.1. AB Science
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Accuray Incorporated
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Elanco Animal Health Incorporated
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Karyopharm Therapeutics, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Morphogenesis, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product portfolio
8.7. PetCure Oncology
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Key strategic moves and developments
8.8. Regeneus Ltd.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Varian Medical System, Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. Zoetis
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
List of Tables
TABLE 01. GLOBAL VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 02. SURGERY VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03. RADIOLOGY VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. CHEMOTHERAPY VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. OTHERS VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06. GLOBAL VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 07. CANINE VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 08. CANINE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030($MILLION)
TABLE 09. FELINE VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 10. FELINE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030($MILLION)
TABLE 11. GLOBAL VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 12. LYMPHOMA VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 13. MAST CELL CANCER VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14. MAMMARY AND SQUAMOUS CELL CANCER VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15. OTHERS VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 16. VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17. NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 18. NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 19. NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 20. NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21. U.S. VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 22. U.S. VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 23. U.S. VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 24. CANADA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 25. CANADA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 26. CANADA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 27. MEXICO VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 28. MEXICO VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 29. MEXICO VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 30. EUROPE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 31. EUROPE VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 32. EUROPE VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 33. EUROPE VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34. GERMANY VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 35. GERMANY VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 36. GERMANY VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 37. FRANCE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 38. FRANCE VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 39. FRANCE VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 40. UK VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 41. UK VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 42. UK VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 43. ITALY VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 44. ITALY VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 45. ITALY VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 46. SPAIN VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 47. SPAIN VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 48. SPAIN VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 49. REST OF EUROPE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 50. REST OF EUROPE VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 51. REST OF EUROPE VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 52. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 53. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 54. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 55. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56. JAPAN VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 57. JAPAN VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 58. JAPAN VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 59. CHINA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 60. CHINA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 61. CHINA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 62. AUSTRALIA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 63. AUSTRALIA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 64. AUSTRALIA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 65. INDIA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 66. INDIA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 67. INDIA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 68. SOUTH KOREA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 69. SOUTH KOREA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 70. SOUTH KOREA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 74. LAMEA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 75. LAMEA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 76. LAMEA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 77. LAMEA VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78. BRAZIL VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 79. BRAZIL VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 80. BRAZIL VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 81. SAUDI ARABIA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 82. SAUDI ARABIA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 83. SAUDI ARABIA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 84. SOUTH AFRICA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 85. SOUTH AFRICA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 86. SOUTH AFRICA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 87. REST OF LAMEA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 88. REST OF LAMEA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 89. REST OF LAMEA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 90. AB SCIENCE: COMPANY SNAPSHOT
TABLE 91. AB SCIENCE: OPERATING SEGMENT
TABLE 92. AB SCIENCE: PRODUCT PORTFOLIO
TABLE 93. ACCURAY: COMPANY SNAPSHOT
TABLE 94. ACCURAY: OPERATING SEGMENT
TABLE 95. ACCURAY: PRODUCT PORTFOLIO
TABLE 96. ACCURAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 98. BOEHRINGER INGELHEIM: OPERATING SEGMENT
TABLE 99. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 100. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101. ELANCO: COMPANY SNAPSHOT
TABLE 102. ELANCO: OPERATING SEGMENT
TABLE 103. ELANCO: PRODUCT PORTFOLIO
TABLE 104. ELANCO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. KARYOPHARM: COMPANY SNAPSHOT
TABLE 106. KARYOPHARM: OPERATING SEGMENT
TABLE 107. KARYOPHARM: PRODUCT PORTFOLIO
TABLE 108. MORPHOGENESIS: COMPANY SNAPSHOT
TABLE 109. MORPHOGENESIS: PRODUCT PORTFOLIO
TABLE 110. PETCURE ONCOLOGY: COMPANY SNAPSHOT
TABLE 111. PETCURE ONCOLOGY: OPERATING SEGMENT
TABLE 112. PETCURE ONCOLOGY: PRODUCT PORTFOLIO
TABLE 113. PETCURE ONCOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. REGENEUS: COMPANY SNAPSHOT
TABLE 115. REGENEUS: OPERATING SEGMENT
TABLE 116. REGENEUS: PRODUCT PORTFOLIO
TABLE 117. VARIAN: COMPANY SNAPSHOT
TABLE 118. VARIAN: OPERATING SEGMENT
TABLE 119. VARIAN: PRODUCT PORTFOLIO
TABLE 120. ZOETIS: COMPANY SNAPSHOT
TABLE 121. ZOETIS: OPERATING SEGMENT
TABLE 122. ZOETIS: PRODUCT PORTFOLIO
TABLE 123. ZOETIS: KEY STRATEGIC MOVES AND DEVELOPMENTSList of Figures
FIGURE 01. VETERINARY ONCOLOGY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF SURGERY VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF RADIOLOGY VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF CHEMOTHERAPY VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF OTHERS VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF CANINE VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF FELINE VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF LYMPHOMA VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF MAST CELL CANCER VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF MAMMARY AND SQUAMOUS CELL CANCER VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF OTHERS VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 23. AB SCIENCE: NET SALES, 2018-2020 ($MILLION)
FIGURE 24. ACCURAY: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. ACCURAY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 26. ACCURAY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 27. BOEHRINGER INGELHEIM: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 29. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 30. ELANCO: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. ELANCO: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 32. ELANCO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 33. KARYOPHARM: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. REGENEUS: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. VARIAN: NET SALES, 2017-2029 ($MILLION)
FIGURE 36. VARIAN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 37. VARIAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38. ZOETIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 39. ZOETIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40. ZOETIS: REVENUE SHARE, BY REGION, 2020 (%)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 257 |
| Published | September 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 297.3 million |
| Forecasted Market Value ( USD | $ 819.84 million |
| Compound Annual Growth Rate | 10.7% |
| Regions Covered | Global |
